Roche: positive data presented at the MDA

(CercleFinance.com) - Roche says it will present new data at the Muscular Dystrophy Association (MDA) conference in Dallas, 16-19 March, from its neuromuscular portfolio, including 12 oral and poster presentations.


According to Roche, Evrysdi's new five-year data from the SUNFISH study showed continued stabilization of motor function in a large population of people with spinal muscular atrophy (SMA) type 2 or 3.

Two-year data from Embark and pooled analysis of studies 101, 102 and Endeavor demonstrated clinically and statistically significant improvements in key measures of motor function in boys with Duchenne muscular dystrophy (DMD).

Muscle pathology measured by MRI continued to generally favor Elevidys in all muscle groups in Duchenne boys up to two years of age, the Swiss pharmaceutical company adds.


Copyright (c) 2025 CercleFinance.com. All rights reserved.